BCL7A. ---. 20.73. 0.46. 1.00. CALML4. +++. 0.60. 0.55. 1.00. TMED2. +++. 20.51. 0.61. 1.00. SPOCK1. ---. 20.44. 0.66. 1.00. DAK. -++. 0.29. 0.77. 1.00. UGT8.
1154
Diabetes Volume 63, March 2014
GENETICS/GENOMES/PROTEOMICS/METABOLOMICS
Sarah Keildson,1 Joao Fadista,2 Claes Ladenvall,2 Åsa K. Hedman,1 Targ Elgzyri,2 Kerrin S. Small,3,4 Elin Grundberg,3,4 Alexandra C. Nica,5 Daniel Glass,3 J. Brent Richards,3,6 Amy Barrett,7 James Nisbet,4 Hou-Feng Zheng,6 Tina Rönn,2 Kristoffer Ström,2,8 Karl-Fredrik Eriksson,2 Inga Prokopenko,1 MAGIC Consortium, DIAGRAM Consortium, MuTHER Consortium, Timothy D. Spector,3 Emmanouil T. Dermitzakis,5 Panos Deloukas,4 Mark I. McCarthy,1,7,9 Johan Rung,10 Leif Groop,2 Paul W. Franks,11 Cecilia M. Lindgren,1,12 and Ola Hansson2
Expression of Phosphofructokinase in Skeletal Muscle Is Influenced by Genetic Variation and Associated With Insulin Sensitivity
Using an integrative approach in which genetic variation, gene expression, and clinical phenotypes are assessed in relevant tissues may help functionally characterize the contribution of genetics to disease susceptibility. We sought to identify genetic variation influencing skeletal muscle gene expression (expression quantitative trait loci [eQTLs]) as well as expression associated with measures of insulin sensitivity. We investigated associations of 3,799,401 genetic variants in expression of >7,000 genes from three cohorts (n = 104). We identified 287 genes with cis-acting eQTLs (false discovery rate [FDR]
